The National Institutes of Health’s (NIH) National Institute on Drug Abuse announced three new funding opportunities aimed at the prevention and treatment of Hepatitis C Virus (HCV) among at-risk individuals using substances. Research may focus on refining HCV screening technologies, HCV prevention and risk-reduction strategies, and HCV treatment options, among others.
NIH uses activity codes to organize and differentiate its award types. For example, activity codes beginning with R support research, and those beginning with K support career development. NIH is soliciting applications for this purpose under the R01, R21, and R34 activity codes. R01s represent the most common type of research grant for a discrete research project typically lasting between 3 to 5 years. An R21 supports new, exploratory and developmental research projects by providing up to 2 years of support for the early stages of project development. Finally, an R34 is a planning grant designed to support the initial development of a clinical trial or research project.
For the current cycle, applications for R01s are due by June 5th. R21s and R34s are due by June 16th.
